Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab for GvHD Prophylaxis in Allo-HSCT
NCT02728895Phase 1Completed
- Sponsor
- Takeda
- Start
- Jun 2016
- Primary completion
- Jul 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of vedolizumab in graft-versus-host disease (GVHD) (3 cohorts), sponsored by Takeda. Primary endpoints: Number of Participants With Dose-Limiting Toxicities at Day 28, Number of Participants Reporting One or More Treatment-emergent Adverse Events and Serious Adverse Events at 18 weeks and 1 more. Started Jun 2016; status: completed.
02
Drugs
vedolizumab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02728895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02728895.